TheraVet SA (ALVET.PA)
EUR 0.11
(-0.46%)
EUR 0.11
(-0.46%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.15 Million EUR | 10.66% |
| 2022 | 1.04 Million EUR | 4.64% |
| 2021 | 1 Million EUR | 43.27% |
| 2020 | 699.1 Thousand EUR | 100.18% |
| 2019 | 349.24 Thousand EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 1.45 Million EUR | 25.35% |
| 2024 Q2 | 1.45 Million EUR | 0.0% |
| 2023 Q4 | 1.15 Million EUR | 0.0% |
| 2023 Q2 | 990.96 Thousand EUR | 0.0% |
| 2023 Q1 | 990.96 Thousand EUR | -5.45% |
| 2023 FY | 1.15 Million EUR | 10.66% |
| 2023 Q3 | 1.15 Million EUR | 17.04% |
| 2022 Q1 | 1.09 Million EUR | 9.0% |
| 2022 Q4 | 1.04 Million EUR | 0.0% |
| 2022 Q3 | 1.04 Million EUR | -4.0% |
| 2022 Q2 | 1.09 Million EUR | 0.0% |
| 2022 FY | 1.04 Million EUR | 4.64% |
| 2021 Q4 | 1 Million EUR | 0.0% |
| 2021 Q1 | 796.58 Thousand EUR | 13.94% |
| 2021 Q2 | 796.58 Thousand EUR | 0.0% |
| 2021 Q3 | 1 Million EUR | 25.74% |
| 2021 FY | 1 Million EUR | 43.27% |
| 2020 Q1 | - EUR | 0.0% |
| 2020 FY | 699.1 Thousand EUR | 100.18% |
| 2020 Q3 | 699.1 Thousand EUR | 16.59% |
| 2020 Q4 | 699.1 Thousand EUR | 0.0% |
| 2020 Q2 | 599.61 Thousand EUR | 0.0% |
| 2019 FY | 349.24 Thousand EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | 65.786% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 97.909% |
| Adocia SA | 13.08 Million EUR | 91.138% |
| Aelis Farma SA | 4.03 Million EUR | 71.276% |
| Biophytis S.A. | 8.27 Million EUR | 85.975% |
| Advicenne S.A. | 17.42 Million EUR | 93.344% |
| genOway Société anonyme | 7.23 Million EUR | 83.965% |
| IntegraGen SA | 1.12 Million EUR | -3.124% |
| Medesis Pharma S.A. | 1.2 Million EUR | 3.344% |
| Neovacs S.A. | 650 Thousand EUR | -78.441% |
| NFL Biosciences SA | 62.17 Thousand EUR | -1765.518% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 73.376% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | 57.308% |
| Sensorion SA | 2.86 Million EUR | 59.569% |
| Theranexus Société Anonyme | 3.64 Million EUR | 68.162% |
| TME Pharma N.V. | 1.16 Million EUR | 0.526% |
| Valbiotis SA | 6.87 Million EUR | 83.137% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | 87.11% |
| argenx SE | 18.1 Million EUR | 93.594% |
| BioSenic S.A. | 28.16 Million EUR | 95.881% |
| Celyad Oncology SA | 902 Thousand EUR | -28.588% |
| DBV Technologies S.A. | 13.01 Million USD | 91.091% |
| Galapagos NV | 9.59 Million EUR | 87.913% |
| Genfit S.A. | 70.17 Million EUR | 98.347% |
| GeNeuro SA | 7.73 Million EUR | 85.01% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | 78.091% |
| Innate Pharma S.A. | 39.89 Million EUR | 97.093% |
| Inventiva S.A. | 37.4 Million EUR | 96.899% |
| MaaT Pharma SA | 14.07 Million EUR | 91.759% |
| MedinCell S.A. | 58.96 Million EUR | 98.033% |
| Nanobiotix S.A. | 50.56 Million EUR | 97.706% |
| Onward Medical N.V. | 16.87 Million EUR | 93.126% |
| Oryzon Genomics S.A. | 13.68 Million EUR | 91.526% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | 97.468% |
| Oxurion NV | 12.33 Million EUR | 90.596% |
| Pharming Group N.V. | 155.29 Million EUR | 99.253% |
| Poxel S.A. | 46.9 Million EUR | 97.527% |
| GenSight Biologics S.A. | 18.42 Million EUR | 93.706% |
| Transgene SA | 1.25 Million EUR | 7.727% |
| Financière de Tubize SA | 79.2 Million EUR | 98.536% |
| UCB SA | 3.03 Billion EUR | 99.962% |
| Valneva SE | 208.81 Million EUR | 99.445% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -2952.282% |